For the purpose of FDA subpart H approval, at 18 months, a histopathologic interim analysis will be performed on the first 750 enrolled patients with fibrosis stage 2-3, to assess for fibrosis improvement 1 point without NASH worsening, or NASH resolution without worsening of fibrosis
The analysis included 43,317 adults with no prior history of cancer who used liraglutide, semaglutide or tirzepatide and 43,315 matched nonusers
Welcome to GoodRx for HCPs
Retatrutide Comparison: Related Research Compounds These compounds collectively provide researchers with tools for investigating incretin receptor biology, metabolic signaling integration, and endocrine pathway regulation
Its a chance to understand whats being overlooked in the rush for quick weight loss, and how your sleep may be quietly suffering in the process